Patients with hypoparathyroidism have increased risk for several health conditions including cataracts, epilepsy, cardiovascular disease, cerebrovascular disease, infection, mental illness, and renal failure.
PTH (1-84) for 7 years is linked to reduced calcium and calcitriol supplementation.
Shire announced the launch of Natpara (parathyroid hormone) for injection indicated as adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism
The FDA has approved Natpara (parathyroid hormone) to control hypocalcemia in patients with hypoparathyroidism.
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted to recommend approval of recombinant human parathyroid hormone for hypoparathyroidism.
Patients with hypoparathyroidism may benefit from treatment with recombinant human parathyroid hormone.
